The National Sleep Foundation conducts a 10-year review of 133 meta-analyses for insights into whether the science has evolved.

The expanded reimbursement access aims to make the FDA-cleared device more affordable for patients with conditions linked to hypoxia.

The American Academy of Sleep Medicine recently recognized nine sleep centers for maintaining AASM accreditation for 40 continuous years, reflecting their long-standing dedication to providing high-quality care for peopl...

On April 14, 2026, the Centers for Medicare & Medicaid Services (CMS) published the Interoperability Standards and Prior Authorization for Drugs Proposed Rule, representing a significant step toward modernizing prior...

New phase 3 data indicate that Takeda’s investigational orexin agonist, oveporexton, significantly improves daily functioning, cognition, and nighttime sleep in patients with narcolepsy type 1.

The integration allows clinicians to manage Onera studies directly within the Somnoware sleep lab management platform.

The investigational oral orexin 2 receptor agonist received designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.

The collaboration integrates data from the ProSomnus RPMO₂ into MonitAir’s platform to support longitudinal tracking.

Researchers have identified 10 molecular biomarkers in saliva that can detect 24-hour sleep deprivation with 94% accuracy, marking a significant step toward developing noninvasive roadside testing. This breakthrough stud...

BALTIMORE – Today, Dr. Fariha Abbasi-Feinberg became president of the American Academy of Sleep Medicine board of directors. She assumed the role during SLEEP 2026, the 40th annual meeting of the nation’s leading sleep m...